**New Treatment Option for Low Sex Drive in Postmenopausal Women** We are pleased to announce that Addyi, also known as "female Viagra," has been approved by the FDA to treat low sex drive in postmenopausal women up to age 65.
**New Treatment Option for Low Sex Drive in Postmenopausal Women**We are pleased to announce that Addyi, also known as "female Viagra," has been approved by the FDA to treat low sex drive in postmenopausal women up to age 65.
This expansion of approval offers new treatment options for older women who may be experiencing low libido. However, our experts emphasize that treating low libido requires a comprehensive approach, taking into account overall health and well-being.
It is essential to note that Addyi should not be taken within two hours of consuming alcohol, as this can lead to potential interactions and side effects such as dizziness or fainting.
**About Addyi**Addyi (flibanserin) is a daily pill approved by the FDA in 2015 for treating hypoactive sexual desire disorder (HSDD) in premenopausal women. The drug was originally developed as an antidepressant but showed promise in improving measures of sexual function.
After two previous rejections, Addyi's approval followed extensive research and a concerted lobbying effort by Even the Score, a group linked to Sprout Pharmaceuticals, its manufacturer.
**What You Need to Know** * Addyi is the only FDA-approved oral medication for HSDD. * The drug carries a warning for potential side effects when combined with alcohol, including low blood pressure and fainting. * It is recommended to wait at least two hours after drinking alcohol before taking Addyi. **Expert Insights**Our experts welcome this expansion of approval as an important step in addressing the unique needs of postmenopausal women. "There was nothing really for me to prescribe because everything was for women who were menstrual and not menopausal," said G. Thomas Ruiz, MD, an OB-GYN at MemorialCare Orange Coast Medical Center.
Mary Jane Minkin, MD, a clinical professor in the department of obstetrics, gynecology, and reproductive sciences at Yale University, noted that the approval was "quite reasonable" given the available data.
Learn more about hair transplant at Rubenhair clinic.
Get a Free Consultation
Consult with our specialists about FUE procedure, PRP therapy or hair transplant.
